Want to see ZYME full AI Analyst Report?

Zymeworks (ZYME) Earnings Dates, Call Summary & Reports

637 Followers

Earnings Data

Report Date

Jul 30, 2026

Before Open (Confirmed)

Period Ending

2026 (Q2)

Consensus EPS Forecast

-0.38

Last Year’s EPS

0.03

Same Quarter Last Year

Analyst Consensus

Strong Buy

Based on 9 Analysts Ratings

Earnings Call Summary

Q1 2026

Earnings Call Date:May 07, 2026|

% Change Since:

Earnings Call Sentiment|Neutral

The call conveyed a mixed but cautiously constructive picture: strong scientific and clinical progress (notably the zanatumab regulatory milestones, compelling ZW191 Phase 1 efficacy signals, and an advancing pan‑RAS ADC preclinical platform) and a materially improved cash balance supported by active buybacks and potential milestone upside. Offsetting this, near‑term GAAP performance showed a sharp revenue decline (‑91.1% YoY) and a widened net loss (≈+95.6%), and the company remains dependent on partner milestones and exposed to ex‑U.S. pricing pressures. Pipeline timing risks (e.g., ZW1528 delayed to 2027) and the need for partnerships to scale certain programs temper the near‑term outlook, but management presented credible funding and strategic plans tied to milestones and disciplined capital allocation.

Company Guidance

The company reiterated near-term regulatory and operational milestones, including a U.S. PDUFA date of 08/25/2026 and an sBLA filing in China for first-line GEA, with near-term approval-triggered milestone payments of $250.0 million (U.S.) and $15.0 million (China) and management citing $440.0 million of anticipated regulatory milestones (U.S./EU/Japan/China) that, together with $403.8 million of cash, cash equivalents and marketable securities as of 03/31/2026 (up from $270.6 million on 12/31/2025), they expect to fund operations beyond 2028 assuming full execution of the $125.0 million repurchase plan; Q1 2026 revenue was $2.4 million versus $27.1 million a year ago, operating expenses were $49.5 million (Q1 2026) versus $52.7 million, and net loss was $44.2 million versus $22.6 million, while share repurchases have used ~$95.8 million of the $125.0 million program to buy ~3.93 million shares at an average $24.37 (total repurchases since 2024 ~ $155.8M for ~8.3M shares at ~$18.70, >10% of shares), leaving ~73 million common shares outstanding; clinical and R&D guidance included ZW191 dose‑optimization (≈60‑patient cohort fully enrolled) with median follow‑up ~7 months, ovarian ORR 56% (>=30% shrinkage in 68%, any shrinkage in 85%, DCR 94%) and at 6.4–9.6 mg/kg ORR 61% with disease control in all patients, endometrial ORR 40% (>=30% shrinkage in 50%, any shrinkage in 70%, DCR 80%) rising to ORR 57% at 6.4–9.6 mg/kg, responses seen from 3.2 mg/kg, ZW1528 IND now guided to 2027 (vs prior 2026), pan‑RAS ADC preclinical program delivered >117 novel inhibitors, three candidate ADCs (ZW439, ZW427, ZW418) were presented at AACR, DAR‑8 format was used, and the lead RAS ADC showed NHP tolerability with no body‑weight, skin or GI toxicity up to 120 mg/kg; additional data cadence was guided toward oncology meetings in 2026 (including ESMO GYN in June).

Near-term Regulatory Catalysts for Zanatumab

PDUFA date set for 08/25/2026 in first-line GEA (U.S.) and sBLA filing completed in China, creating visible near-term commercialization pathway with partners Jazz and BeiGene and potential for meaningful milestone and royalty revenue.

Material Potential Milestone Upside

Potential near-term milestone payments include $250M upon U.S. approval from Jazz and $15M upon China approval from BeiGene; management cites anticipated regulatory milestone payments of $440M across U.S., Europe, Japan and China that underpin financial runway assumptions.

Strong Cash Position and Runway

Cash, cash equivalents and marketable securities of $403.8M as of 03/31/2026, up from $270.6M as of 12/31/2025 (+49.2%), with management expecting existing cash plus anticipated milestone payments to fund operations beyond 2028 (assumes milestones).

Active Share Repurchase Program

Company has used ~$95.8M of its $125M repurchase authorization (~76.6% utilized) to acquire ~3.93M shares at an average price of $24.37; historically retired ~8.3M shares (~$155.8M deployed) representing >10% of common shares outstanding, reflecting disciplined capital allocation to increase per-share value.

Compelling Phase 1 Data for ZW191 (FRα ADC)

ZW191 showed notable activity in heavily pretreated ovarian and endometrial cohorts: ovarian cohort ≥30% tumor regression in 68%, any tumor shrinkage in 85%, disease control 94%, ORR 56% across dose levels; at 6.4–9.6 mg/kg confirmed ORR 61% and disease control in all patients at that range. Endometrial: ≥30% tumor regression in 50%, tumor shrinkage in 70%, disease control 80%, ORR 40% (all doses); at 6.4–9.6 mg/kg ORR 57% and disease control 86%. Median follow-up ~7 months with durability signals.

Pan‑RAS ADC Platform and Preclinical Progress

Presented three new preclinical pan‑RAS ADC candidates (ZW439: Claudin 18.2; ZW427: L1CAM; ZW418: biparatopic PTK7) at AACR and proprietary TOPA payload advancement. Lead pan‑RAS ADC showed favorable xenograft efficacy, bystander activity, and promising NHP tolerability with no observed body weight loss, skin or GI toxicity up to 120 mg/kg in tolerability studies. ADCs are DAR‑8 formats enabling tumor-selective payload delivery.

ZW251 Trial Expansion and TriTCE Progress

ZW251 protocol broadened to include additional tumor types (e.g., squamous NSCLC and germ cell tumors) based on GPC3 expression rationale; ZW209 is IND‑ready and TriTCE portfolio remains a prioritized long‑term asset class.

Operational and Leadership Strengthening

Appointed new CFO and General Counsel and completed full-time appointments for commercial and R&D heads to support capital allocation, dealmaking, and strategic execution.

Zymeworks (ZYME) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ZYME Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jul 30, 2026	2026 (Q2)	-0.38 / -	0.03	―	―	―
May 07, 2026	2026 (Q1)	-0.30 / -0.59	-0.3	-96.67% (-0.29)
Mar 02, 2026	2025 (Q4)	-0.46 / -0.55	-0.31	-77.42% (-0.24)
Nov 06, 2025	2025 (Q3)	-0.29 / -0.26	-0.39	33.33% (+0.13)
Aug 07, 2025	2025 (Q2)	-0.48 / 0.03	-0.49	106.12% (+0.52)
May 08, 2025	2025 (Q1)	-0.68 / -0.30	-0.42	28.57% (+0.12)
Mar 05, 2025	2024 (Q4)	-0.10 / -0.31	-0.2	-55.00% (-0.11)
Oct 31, 2024	2024 (Q3)	-0.40 / -0.39	-0.41	4.88% (+0.02)
Aug 01, 2024	2024 (Q2)	-0.42 / -0.49	-0.76	35.53% (+0.27)
May 02, 2024	2024 (Q1)	-0.32 / -0.42	-0.37	-13.51% (-0.05)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ZYME Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 07, 2026	$26.60	$23.89	-10.19%
Mar 02, 2026	$23.29	$23.31	+0.09%
Nov 06, 2025	$17.90	$16.46	-8.04%
Aug 07, 2025	$12.16	$12.02	-1.15%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Zymeworks (ZYME) report earnings?

Zymeworks (ZYME) is schdueled to report earning on Jul 30, 2026, Before Open (Confirmed).

What is Zymeworks (ZYME) earnings time?

Zymeworks (ZYME) earnings time is at Jul 30, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ZYME EPS forecast?

ZYME EPS forecast for the fiscal quarter 2026 (Q2) is -0.38.